BCTXW
Income statement / Annual
Last year (2023), BriaCell Therapeutics Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, BriaCell Therapeutics Corp.'s net income was -$20.30 M.
See BriaCell Therapeutics Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
07/31/2023 |
07/31/2022 |
07/31/2021 |
07/31/2020 |
07/31/2019 |
07/31/2018 |
07/31/2017 |
07/31/2016 |
07/31/2015 |
07/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$20,490.00
|
$19,385.00
|
$19,441.00
|
$18,741.00
|
$18,743.00
|
$16,894.00
|
$290.00
|
$1,790.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$20,490.00
|
-$19,385.00
|
-$19,441.00
|
-$18,741.00
|
-$18,743.00
|
-$16,894.00
|
-$290.00
|
-$1,790.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$15.34 M
|
$8.02 M
|
$1.32 M
|
$2.22 M
|
$3.74 M
|
$2.39 M
|
$1.71 M
|
$723,428.00
|
$105,824.00
|
$0.00
|
| General & Administrative Expenses |
$7.94 M
|
$7.27 M
|
-$3.67 M
|
-$1.37 M
|
-$932,169.26
|
-$1.05 M
|
$876,162.00
|
$942,018.00
|
$1.33 M
|
$436,166.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.94 M
|
$7.27 M
|
-$3.67 M
|
-$1.37 M
|
-$932,169.26
|
-$1.05 M
|
$876,162.00
|
$942,018.00
|
$1.33 M
|
$436,166.00
|
| Other Expenses |
$0.00
|
-$15.29 M
|
-$1.33 M
|
-$2.24 M
|
-$3.75 M
|
-$312,917.04
|
$232.68
|
$1,370.39
|
$434.31
|
$1,108.24
|
| Operating Expenses |
$23.27 M
|
-$3,388.00
|
-$3.69 M
|
-$1.38 M
|
-$946,423.36
|
-$1.07 M
|
$2.58 M
|
$1.67 M
|
$1.44 M
|
$437,274.00
|
| Cost And Expenses |
$23.27 M
|
-$3,388.00
|
-$3.69 M
|
-$1.38 M
|
-$946,423.36
|
-$1.07 M
|
$2.58 M
|
$1.67 M
|
$1.44 M
|
$437,274.00
|
| Interest Income |
$891,213.00
|
$136,731.00
|
$3,149.00
|
$39.48
|
$9,129.07
|
$12,273.00
|
$5,157.46
|
$3,627.32
|
$7,092.67
|
$11,997.00
|
| Interest Expense |
$0.00
|
$979.00
|
$46,095.00
|
$26,995.00
|
$23,816.00
|
$15,629.00
|
$5,157.46
|
$3,627.32
|
$7,092.67
|
$11,997.00
|
| Depreciation & Amortization |
$15,271.00
|
$19,385.00
|
$19,441.00
|
$18,741.00
|
$18,743.00
|
$16,894.00
|
$290.00
|
$1,790.00
|
$434.31
|
$1,108.24
|
| EBITDA |
-$27.22 M |
-$34.05 M |
-$17.49 M |
-$4.89 M |
-$5.74 M |
-$5.38 M |
-$3.22 M |
-$2.21 M |
-$3.49 M |
-$8.89 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.97 M
|
-$18.78 M
|
-$6.84 M
|
-$85,097.00
|
$905,296.00
|
-$1.59 M
|
-$2,485.00
|
-$37,586.00
|
-$1.24 M
|
-$7.71 M
|
| Income Before Tax |
-$20.30 M
|
-$11.55 M
|
$3.69 M
|
$1.38 M
|
$946,423.00
|
$1.07 M
|
-$2.58 M
|
-$1.70 M
|
-$2.68 M
|
-$8.15 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$152,624.00
|
$30,730.00
|
$6.58 M
|
-$72,250.96
|
$343,743.00
|
-$319,123.82
|
$1,993.82
|
$29,238.00
|
$1.24 M
|
$7.71 M
|
| Net Income |
-$20.30 M
|
-$11.58 M
|
-$2.89 M
|
$1.38 M
|
$602,680.00
|
$1.07 M
|
-$2.58 M
|
-$1.70 M
|
-$2.68 M
|
-$8.15 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.74 |
-0.75 |
-0.19 |
1.94 |
1.04 |
2.49 |
-7.61 |
-5.88 |
-10.76 |
-138.07 |
| EPS Diluted |
-1.74 |
-0.75 |
-0.19 |
1.94 |
1.04 |
2.49 |
-7.32 |
-5.88 |
-10.76 |
-138.07 |
| Weighted Average Shares Out |
$15.62 M
|
$15.49 M
|
$15.27 M
|
$713,889.00
|
$579,663.00
|
$427,814.00
|
$339,707.00
|
$288,443.00
|
$249,178.00
|
$59,002.00
|
| Weighted Average Shares Out Diluted |
$15.62 M
|
$15.52 M
|
$15.27 M
|
$713,889.00
|
$579,664.00
|
$427,815.00
|
$352,979.00
|
$288,443.00
|
$249,178.00
|
$59,002.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
